AbbVie Inc. / Halozyme Therapeutics, Inc. (ENHANZE platform)

Multiple (subcutaneous reformulation of biologics, lead target TNF-α / Humira)

Disease Overview

Halozyme's ENHANZE platform is a recombinant human hyaluronidase (rHuPH20) that temporarily degrades hyaluronan in subcutaneous tissue, enabling rapid SC delivery of large-volume biologics that would otherwise require IV infusion. The platform is indication-agnostic — applied to oncology antibodies, immunology biologics and immunoglobulins — and the AbbVie deal targeted up to nine biologic targets, with TNF-α (Humira/adalimumab) selected as the first.

Competitive Landscape

ENHANZE is the dominant SC-delivery enabling platform for biologics, validated by Roche's Herceptin SC, MabThera SC, Phesgo and Tecentriq SC; J&J's Darzalex Faspro; and BMS's Opdivo SC. Competing approaches include Eagle/Acacia's high-concentration formulation work and Alteogen's ALT-B4 hyaluronidase (licensed to Merck for Keytruda SC, an ENHANZE competitor). The 2015 AbbVie-Halozyme deal applied ENHANZE to up to nine AbbVie targets, with Halozyme receiving $23M upfront and up to ~$130M in milestones per target (~$1.17B aggregate) — a structurally typical ENHANZE bio-bucks contract. AbbVie's first nominated target was TNF-α, paired with Humira. On November 21, 2016, AbbVie discontinued the TNF-α program after a Phase 1 study failed to achieve target results (biopharmadive.com 2016-11-21; biospace.com 2016-11-21). Halozyme stock 'tumbled' on the news, eliminating future milestone payments tied to that target, and BioPharma Dive characterized it as a missed opportunity to extend Humira's lifecycle — particularly material given Humira's ~$15B+ peak sales and impending biosimilar exposure. While the broader 2015 collaboration framework formally remained open for additional targets, AbbVie did not progress further programs and the relationship effectively wound down.